drugset / Trial / NCT02094729
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in subjects with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.
Timeline
- Start
- 2013-09
- Primary completion
- 2015-03
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lecanemab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Lecanemab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Lecanemab | Monoclonal antibody | 10 mg/kg | Intravenous |